Next Article in Journal
Common Variable Immunodeficiency and Gastric Malignancies
Next Article in Special Issue
New Insights into the Tumor Microenvironment Utilizing Protein Array Technology
Previous Article in Journal
Beyond the Matrix: The Many Non-ECM Ligands for Integrins
Previous Article in Special Issue
Halfway between 2D and Animal Models: Are 3D Cultures the Ideal Tool to Study Cancer-Microenvironment Interactions?
Article Menu
Issue 2 (February) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2018, 19(2), 450; https://doi.org/10.3390/ijms19020450

The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression

1
Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, VIC 3052, Australia
2
The Hudson Institute of Medical Research, Clayton, VIC 3168, Australia
3
Fiona Elsey Cancer Research Institute, Ballarat, VIC 3353, Australia
4
Federation University Australia, Ballarat, VIC 3010, Australia
*
Author to whom correspondence should be addressed.
Received: 19 December 2017 / Revised: 23 January 2018 / Accepted: 24 January 2018 / Published: 2 February 2018
(This article belongs to the Special Issue Tumor Microenvironment)
View Full-Text   |   Download PDF [4759 KB, uploaded 2 February 2018]   |  

Abstract

Approximately sixty per cent of ovarian cancer patients die within the first five years of diagnosis due to recurrence associated with chemoresistance. The metzincin family of metalloproteinases is enzymes involved in matrix remodeling in response to normal physiological changes and diseased states. Recently, there has been a mounting awareness of these proteinases and their endogenous inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), as superb modulators of cellular communication and signaling regulating key biological processes in cancer progression. This review investigates the role of metzincins and their inhibitors in ovarian cancer. We propose that understanding the metzincins and TIMP biology in ovarian cancer may provide valuable insights in combating ovarian cancer progression and chemoresistance-mediated recurrence in patients. View Full-Text
Keywords: metzincins; ovarian cancer; metastasis; matrix metalloproteinases (MMPs); disintegrin and metalloproteinases (ADAMs); ADAM proteases with thrombospondin motifs (ADAMTS); TIMPs metzincins; ovarian cancer; metastasis; matrix metalloproteinases (MMPs); disintegrin and metalloproteinases (ADAMs); ADAM proteases with thrombospondin motifs (ADAMTS); TIMPs
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Escalona, R.M.; Chan, E.; Kannourakis, G.; Findlay, J.K.; Ahmed, N. The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression. Int. J. Mol. Sci. 2018, 19, 450.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top